London-based dementia care startup Punto Health has raised €2.3 million ($2.7 million) in a Seed funding round to accelerate product development and commercial expansion across the UK and Spain.
The round was co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.
“Dementia is never just one person’s disease. It affects entire families, and carers often carry an enormous invisible burden. We are building technology that turns a reactive, crisis-driven system into proactive, personalised support that fits into people’s real lives,” said Anna Muñoz-Farré, CEO and co-founder of Punto Health.
Earlier this year, in June, the company won the second edition of the NN Social Innovation Startup Award at The Next Web Conference in Amsterdam. It received €100k plus a year-long mentorship programme from NN Group and Rubio Impact Ventures. Prior to that, in May 2024, Punto Health closed a €645k investment round. The company claims that this Seed round builds on a €718.5k ($840k) pre-Seed investment.
Founded in 2023 in London by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health is a digital health company developing AI-powered tools for early detection and personalised support in dementia and cognitive decline.
The company claims to have built an operating system for dementia care: a multilingual digital platform that connects patients, carers, and clinicians across three core products. PuntoTest is an AI-powered, speech-based digital test for assessing cognitive impairment in adults. PuntoCare is a companion app for patients, carers, and active seniors. It provides care plans, cognitive stimulation exercises, nutrition advice, symptom tracking, physical activity guidance, and other wellness support. Its clinician-facing dashboard is called PuntoClinic. It aggregates patient-reported outcomes and biomarker data to support more personalised, data-driven decision-making, while also supporting clinicians and researchers.
Punto Health’s platform is co-designed and clinically validated in partnership with Ace Alzheimer Centre Barcelona. Together, they are building a speech-based digital biomarker that can detect changes in cognitive status, providing clinicians with a detailed view of disease progression across multiple cognitive domains.
According to the company, in Spain, PuntoTest has already been tested in a rapid cognitive screening programme, alongside Ace Alzheimer Centre and Nutricia, across ten pharmacies in Barcelona, and involving more than 1,500 participants aged 50 and above.
The platform is also being piloted at North London NHS FT, NHS Oxleas FT, Hospital del Mar in Barcelona and Hospital General de Granollers, amongst others.
It now supports more than 200 users, aged 60 to 90, who have completed over 30,000 activities, with more than two-thirds reporting improved confidence in managing their day-to-day routines.
“As a technical founder, I have the chance to build a team that looks more like the real world, and to show young women that they belong in AI and health tech. But most of all, I want families to feel they have a trusted companion at every step, not just a diagnosis and a pile of leaflets,” said Muñoz-Farré.
The company is a finalist in VIII Edición de los Premios Discapnet by Fundación ONCE. It has also been selected to be part of programmes such as the AD Moonshot by Startup Health, the Alzheimer’s Drug Discovery Foundation, and the AI-First Google Accelerator 2025.
Read the orginal article: https://www.eu-startups.com/2025/12/londons-punto-health-raises-e2-3-million-scale-ai-powered-full-stack-platform-dementia-care/
